APM
BEAM icon

Avidity Partners Management’s Beam Therapeutics BEAM Stock Holding History

Avidity Partners Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-112,000
Closed -$2.72M – 45
2025
Q3 		$2.72M Sell
112,000
-297,400
-73% -$5.92M 0.62% 35
2025
Q2 		$6.96M Sell
409,400
-300,117
-42% -$5.23M 1.39% 26
2025
Q1 		$13.9M Buy
+709,517
New +$18.6M 2.64% 10

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Avidity Partners Management's BEAM Position: Q4 2025 in Review

Avidity Partners Management sold out of Beam Therapeutics (BEAM) in Q4 2025, closing a stake of 112,000 shares — an estimated $2.72M sold.

Avidity Partners Management first reported a position in BEAM in Q1 2025 and held it in 3 quarters. The position peaked at $13.9M in Q1 2025. 247 funds tracked by Wall St. Rank hold BEAM as of Q4 2025.

  • Avidity Partners Management reported no remaining Beam Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Avidity Partners Management sold 112,000 Beam Therapeutics shares in Q4 2025, an estimated $2.72M.
  • Avidity Partners Management first reported a position in Beam Therapeutics in Q1 2025 and held it in 3 quarters.
  • Avidity Partners Management's Beam Therapeutics position peaked at $13.9M in Q1 2025.
  • 247 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2025.

Based on Avidity Partners Management's 13F filing for Q4 2025, filed 13 Feb 2026.